Pharmacological intervention at disparate sites in the coagulation cascade: Comparison of anti-thrombotic efficacy vs. bleeding propensity in a rat model of acute arterial thrombosis

Journal of Thrombosis and Thrombolysis

Volumn 14, Issue 2, 2002, Pages 113-121

  Szalony, James A ^a   Taite, Beatrice B ^a   Girard, Thomas J ^a   Nicholson, Nancy S ^a   LaChance, Rhonda M ^a  

^a Pharmacia ^*  (United States)

Author keywords

Anticoagulation; Bleeding; Issue factor; Thrombosis

Indexed keywords

1 (2 AMINO 6 METHYL 5 PYRIDINYLMETHYLAMINOCARBONYLMETHYL) 3 BENZYLSULFONAMIDO 6 METHYL 2 PYRIDINONE; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A INHIBITOR; SC 79407; SC 83157; SERINE PROTEINASE; SN 429; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; XK1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY OCCLUSION; ARTICLE; BLEEDING TENDENCY; BLEEDING TIME; BLOOD CLOTTING; BLOOD VOLUME; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOSE RESPONSE; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; INHIBITION KINETICS; MALE; NONHUMAN; PHARMACOLOGICAL PROCEDURES; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ACUTE DISEASE; ANIMALS; BLEEDING TIME; BLOOD COAGULATION FACTORS; CAROTID ARTERY THROMBOSIS; CAROTID ARTERY, COMMON; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0037541104     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023228827733     Document Type: Article

References (21)

1. Braunwald E, Califf RM, Cannon CP, et al. Redefining medical treatment in the management of unstable angina. Am J Med 2000;108:41-53.
2. Moreno PR, Bernardi VH, Lopez-Cuellar J, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina: Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996;94:3090-3097.
3. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemosta 1991;66:67-79.
4. Taubman MB, Fallon JT, Schecter AD, et al. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost 1997;78:200-204.
5. Giesen PLA, Fyfe BS, Fallon JT, et al. Intimal tissue factor activity is released from the arterial wall after tissue injury. Thromb Haemost 2000;83:622-628.
6. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258-264.
7. Hauptmann J, Sturzebecher J. Synthetic inhibitors of thrombin and factor Xa: Form bench to bedside. Thromb Res 1999;93:203-241.
8. Sanderson PE, Lyle TA, Cutrona KJ, et al. Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates. J Med Chem 1998;41:4466-4474.
9. Hara T, Yokoyama A, Morishima Y, Kunitada S. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb Res 1995;80:99-104.
10. Pinto DJP, Orwat MJ, Wang S, et al. Discovery of 1-(3-(Aminomethyl)phenyl)-N-(3-fluoro-2-methylsulfonyl)-(1,1-biphenyl)-4-yl)-3-( trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2001;44:566-578.
11. Girard TJ, MacPhail LA, Likert KM, Novotny WF, Milletich JP, Broze GJ, Jr. Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein. Science 1990;248:1421-1424.
12. Cook JJ, Gardell SJ, Holohan MA, et al. Antithrombotic efficacy of thrombin inhibitor L-374, 087: Intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis. J Pharmacol Exper Ther 1999;289:503-510.
13. Harker LA, Hanson SR, Wilcox JN, Kelly AB. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemost 1996;26(suppl 1):76-82.
14. Himber J, Kirchhofer D, Riedereer M, Tschopp TB, Steiner B, Roux SP. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemost 1997;78:1142-1149.
15. Zoldhelyi P, McNatt J, Shelat HS, Yamamoto Y, Chen Z-Q, Willerson JT. Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation 2000;101:289-295.
16. Smith GF, Neubauer BL, Sundboom JL, et al. Correlation of the in vivo anticoagulant, antithrombotic, and antimetastatic efficacy of warfarin in the rat. Thromb Res 1988;50:163-174.
17. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990;260:269-280.
18. Broersma RJ, Kutcher LW, Heminger EF. The effect of thrombin inhibition in a rat arterial thrombosis model. Thromb Res 1991;64:405-412.
19. Giesen PLA, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci 1999;96:2311-2315.
20. Conricode KM, LaChance RM, Girard TJ. Inhibition of endotoxin-induced coagulation in rats by XK1, a potent and selective tissue factor-factor VIIa inhibitor. Blood 2000;96:54A.
21. Han X, Girard TJ, Baum P, Abendschein DR, Broze GJ, Jr. Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat. Arterio Thromb Vasc Biol 1999;19:2563-2567.